Akebia Therapeutics Acquires Global Rights to AKB-097 from Q32 Bio
I'm PortAI, I can summarize articles.
Akebia Therapeutics Inc. has acquired global rights to AKB-097 from Q32 Bio through an Asset Purchase Agreement. Akebia paid $7 million upfront and will pay an additional $3 million after six months. The agreement includes potential milestone payments and tiered royalties on AKB-097 sales. This news was generated by Public Technologies using AI and is based on Akebia's original content published via GlobeNewswire.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments